Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Intouch Placement - Wide Discount to NAV but Could Be Held Back by Overhang

Intouch: Temasek Trims Stake; More To Come

Reality Check XXVI: How Much Are the Other Intuch VC Investments Worth?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Intouch Holdings / Equity Capital Markets

<p>Intouch announced a UD 500 million secondary share placement. In this insight, we will provide our quick view on the deal. We think Intouch is trading at an attractive holdco discount. We also note that past deals have done well. </p>

Intouch announced a UD 500 million secondary share placement. In this insight, we will provide our quick view on the deal. We think Intouch is trading at an attractive holdco discount. We also note that past deals have done well. 

Intouch Placement: Attractive Holdco Discount and Good Track Record of past Deals